FDA Grants Approval to Foundayo Weight Loss Pill
The U.S. Food and Drug Administration announced on Tuesday the approval of Foundayo, a once-daily oral weight loss medication developed by NovaThin Pharmaceuticals. The drug represents a major milestone in obesity treatment, offering patients a convenient pill-based alternative to injectable GLP-1 receptor agonist therapies that have dominated the market.
Clinical Trial Results
In a Phase III clinical trial involving over 4,500 participants, patients taking Foundayo lost an average of 22% of their body weight over 68 weeks. The results were described as groundbreaking by researchers at the Mayo Clinic who participated in the study.
This is the first oral medication that approaches the efficacy we have seen with injectable GLP-1 drugs like semaglutide. It could be a game-changer for millions of Americans struggling with obesity.
The trial also showed significant improvements in cardiovascular risk markers, including a 15% reduction in LDL cholesterol and improved blood pressure readings across all participant groups.
How Foundayo Works
Foundayo combines two mechanisms of action: it activates GLP-1 receptors similarly to drugs like Wegovy and Ozempic, while also targeting the GIP receptor pathway. This dual-action approach is what researchers believe accounts for its impressive weight loss results in a pill form.
- Once-daily oral tablet taken with water in the morning
- Gradual dose escalation over 8 weeks to minimize side effects
- Available in 5mg, 10mg, and 15mg doses
- Approved for adults with BMI of 30+ or 27+ with comorbidities
Side Effects and Safety
The most commonly reported side effects include nausea, which affected approximately 28% of participants during the dose escalation phase, diarrhea, and mild headaches. Most side effects resolved within the first four weeks of treatment. Serious adverse events were rare and occurred at rates similar to placebo.
Availability and Cost
NovaThin expects Foundayo to be available in pharmacies by mid-May 2026. The list price has not yet been announced, but analysts estimate it could be priced between $800 and $1,200 per month without insurance, comparable to existing GLP-1 therapies. Several major insurers have already indicated they plan to cover the medication.
The approval comes at a time when demand for weight loss medications continues to surge, with the global obesity drug market projected to exceed $150 billion by 2030.
